

Summary Public Assessment Report

Calcomben (cholecalciferol, calcium carbonate)

SE/H/2549/01-03/DC

Summary Public Assessment Report

Calcomben
cholecalciferol, calcium carbonate

Chewable tablet, 500 mg/400 IE, 500 mg/800 IE, 1000 mg/800 IE

This is a summary of the public assessment report (PAR) for Calcomben. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Calcomben and what is it used for?

The product is a medicine with 'well-established use'. This means that the medicinal use of the active substance of the product is well established in the European Union for at least ten years, with recognised efficacy and an acceptable level of safety.

Calcomben is used to prevent and treat calcium and vitamin D deficiency in adults and elderly, and as a supplement in the treatment of osteoporosis, when a risk of deficiency of calcium or vitamin D is suspected.

How does Calcomben work?

Calcomben contains calcium and vitamin D, both of which are important components for the formation of bone. Vitamin D regulates the uptake and metabolism of calcium as well as the incorporation of calcium in bone tissue.

How is Calcomben used?

The pharmaceutical form is chewable tablet for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Calcomben have been shown in studies?

As cholecalciferol, calcium carbonate is a well-known substance, and its use to prevent and treat calcium and vitamin D deficiency in adults and elderly, and as a supplement in the treatment of osteoporosis, when a risk of deficiency of calcium or vitamin D is suspected is well established, the applicant presented data from the scientific literature. The literature provided confirmed the efficacy and safety of cholecalciferol, calcium carbonate in the treatment of the above-mentioned indication.

What are the possible side effects from Calcomben?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Calcomben approved?

The Swedish Medical Products Agency decided that the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Calcomben?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Calcomben

The full PAR for Calcomben can be found on the following website: [MRI - Home](#). For more information about treatment with Calcomben, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2026-06.